| 產品名稱 |
Human Coxsackievirus B3 |
| 商品貨號 |
B162778 |
| Classification |
Picornaviridae, Enterovirus, Human enterovirus B |
| Deposited As |
Coxsackievirus B3 |
| Agent |
Human Coxsackievirus B3 |
| Strain |
Nancy |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
frozen 1 mL per vial |
| Storage Conditions |
-70°C or colder |
| Comments |
Cryopreserved in 10% FBS. |
| Effect on Host |
CPE, refractile rounding and sloughing |
| Recommended Host |
LLC-MK2 (ATCC® CCL-7.1™) |
| Growth Conditions |
Temperature: 37°C
Recommendations for Infection: Plate cells 24-48 hours prior to infection and infect when cultures are 80-90% confluent. Remove medium and inoculate with a small volume of virus (e.g. 1 mL per 25 cm 2) diluted to provide an optimal MOI (e.g. 0.1). Adsorb 1-2 hours at 37°C in a humidified 5% CO 2 atmosphere, rocking every 20-30 minutes to redistribute inoculum. End adsorption by adding virus growth medium.
|
| Name of Depositor |
JL Melnick |
| Source |
Stool from febrile patient with minor illness, Connecticut, 1949 |
| References |
Melnick JL, Ledinko N. Immunological reactions of the Coxsackie viruses. I. The neutralization test; technic and application. J. Exp. Med. 92: 463-482, 1950. PubMed: 14778925
|
| Cross References |
Nucleotide (GenBank) :
AJ295194
Human coxsackievirus B3 genomic RNA for partial polyprotein gene, isolate VR-30, ATCC.
|
